A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Ovarian Cancer News Today has covered TapImmune’s cancer vaccine for Ovarian and Breast Cancer, TPIV 200. Take a look.
The company is getting closer with several therapies under development, CEO Glynn Wilson said in a quarterly update last week.
Here is the complete transcript provided by Seeking Alpha from May 31st conference call and live webcast regarding 2017 first quarter clinical and corporate updates.
TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha
Targeting the immune system to fight cancer is not new: in 1891, New York bone sarcoma surgeon William B. Coley injected a patient with an inoperable malignant tumor with streptococcal organisms. His theory was that the resulting severe bacterial infection, erysipelas, would stimulate the immune system, shrinking the tumor.
On May 1st, TapImmune announced Richard Kenney, MD, FACP, was joining TapImmune to lead the Clinical Development Program. Dr. Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.
TapImmune is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense.